New therapies for reducing low-density lipoprotein cholesterol

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 4, 2014, Pages 1007-1033

  Stein, Evan A ^a   Raal, Frederick J ^b  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Apo B antisense; LDL cholesterol; MTP inhibitors; PCSK9 inhibitors

Indexed keywords

ALIROCUMAB; ANACETRAPIB; ATORVASTATIN; BOCOCIZUMAB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EVACETRAPIB; EVOLOCUMAB; HYPOCHOLESTEROLEMIC AGENT; IMPLITAPIDE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DISEASE SEVERITY; DRUG APPROVAL; DRUG BINDING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LIVER TOXICITY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE;

EID: 84964265734     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2014.08.008     Document Type: Review

References (93)

1. Statins: a success story involving FDA, academia and industry. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/Selections FromFDLIUpdateSeriesonFDAHistory/ucm082054.htm. Accessed July 25, 2014.
2. Stone N, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45.
3. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
4. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29:151-67.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: an expert guide to clinical practice for secondary prevention of coronary heart disease. Melbourne (Australia): National Heart Foundation of Australia; 2012. Available at: http://www. heartfoundation.org.au/SiteCollectionDocuments/Reducing-risk-inheart-disease. pdf. Accessed July 10, 2014.
6. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
7. Jones PH, Davidson MH, Stein EA, et al, STELLAR Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60.
8. LaRosa JC, Grundy SM, Waters DD, et al, Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35.
9. Billups SJ, Plushner SL, Olson KL, et al. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm 2005;11(8):681-6.
10. Jackevicius CA, Chou MM, Ross JS, et al. Generic atorvastatin and health care costs. N Engl J Med 2012;366(3):201-4.
11. Howard L. Drug in focus: rosuvastatin. Available at: http://www.genericsweb. com/index.php?object_id5680. Accessed July 12, 2014.
12. Available at: http://www2.costco.com/Pharmacy/DrugInfo.aspx?p51&Search Term5atorvastatin&Drug5ATORVASTATIN. Accessed July 12, 2014.
13. Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41(9):943-9.
14. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159(16):1893-900.
15. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extendedrelease niacin (Niaspan): a long-term study. Am J Cardiol 1998;82(12A): 74U-81U.
16. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 1987;83(5B):50-9.
17. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013;15(1): 291.
18. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of Fluvastatin XL 80 mg alone, ezetimibe alone and the combination of Fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, double-blind, double-dummy trial. Am J Cardiol 2008; 101:490-6.
19. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
20. Stein E, Stender S, Mata P, et al, Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148(3):447-55.
21. Stein EA, Ose L, Retterstol K, et al. Further reductions in low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol 2007;1:280-6.
22. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013;34:3478-90.
23. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014;129:1022-32.
24. FDA approves new orphan drug for rare cholesterol disorder. US Food and Drug Administration Web site. 2012. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm333285.htm. Accessed May 28, 2014.
25. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. US Food and Drug Administration Web site. 2013. Available at: http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm. Accessed May 28, 2014.
26. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35.
27. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1413-9.
28. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126:2283-92.
29. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebocontrolled trial. Lancet 2010;375:998-1006.
30. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51(5):1057-62.
31. A Study of the safety and efficacy of two different regimens of mipomersen in patients with familial hypercholesterolemia and inadequately controlled lowdensity lipoprotein cholesterol (FOCUS FH). Available at: http://clinicaltrials. gov/show/NCT01475825. Accessed July 12, 2014.
32. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_ of_opinion_-_Initial_authorisation/human/002429/WC500140678.pdf. Accessed July 12, 2014.
33. Available at: http://www.forbes.com/sites/larryhusten/2013/03/22/europe-andus- diverge-on-two-new-drugs/. Accessed July 12, 2014.
34. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258: 999-1001.
35. Scriver CR, Sly WS, Childs B, et al, editors. The metabolic and molecular bases of inherited disease. 8th edition. McGraw-Hill Professional; 2000.
36. Rader DJ, Brewer HB Jr. Abetalipoproteinemia: new insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA 1993;270: 865-9.
37. Stein EA, Isaacsohn JL, Mazzu A, et al. Effect of BAY 13-9952, a microsomal triglyceride transfer protein inhibitor on lipids and lipoproteins in dyslipoproteinemic patients. Circulation 1999;100(18 Suppl 1) [abstract: 1342].
38. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1999;282:751-4.
39. Farnier M, Stein E, Megnien S, et al. Efficacy and safety of implitapide, a microsomal triglyceride transfer protein inhibitor in patients with primary hypercholesterolemia. Abstract Book of the XIV International Symposium on Drugs Affecting Lipid Metabolism. New York, September 9-12, 2001. p. 4.
40. Available at: http://www.clinicaltrials.gov/ct/show/NCT00079859. Accessed June 10, 2008.
41. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-56.
42. Available at: http://www.sec.gov/Archives/edgar/data/1338042/000119312 507123502/ds1a.htm. Aegerion Pharmaceuticals, Inc. Common Stock Registration Statement. AMENDMENT NO. 3 to FORM S-1; May 25, 2007. United States Securities and Exchange Commission. Washington, DC. 20549. 2007. Accessed July 12, 2014.
43. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5:497-505.
44. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40-6.
45. Efficacy and safety of lomitapide in Japanese patients with HoFH on concurrent lipid-lowering therapy. Available at: http://clinicaltrials.gov/ct2/show/record/ NCT02173158?term5lomitapide&rank58. Accessed July 12, 2014.
46. Stein EA, Raal FJ. Reduction of low density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014;65:417-31.
47. Tall AR, Jiang X, Luo Y, et al. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:1185-8.
48. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24:490-7.
49. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65.
50. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
51. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367(22):2089-99.
52. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
53. Maxwell KN, Breslow JL. Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004;101:7100-5.
54. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005;102(6):2069-74.
55. Rashid S, Curtis DE, Garuti R, et al. Horton decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci U S A 2005;102:5374-9.
56. CohenJC, BoerwinkleE, Mosley THJr, etal.SequencevariationsinPCSK9, lowLDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
57. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of lossof- function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79(3):514-23.
58. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116:2995-3005.
59. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009;106:9820-5.
60. Berthold HK, Seidah NG, Benjannet S, et al. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One 2013;8(3):e60095. http://dx.doi.org/10.1371/journal.pone.0060095.
61. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-83.
62. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-98.
63. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Available at: http://clinicaltrials.gov/show/ NCT01764633. Accessed July 12, 2014.
64. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with Alirocumab SAR236553 (REGN727). Available at: http://clinicaltrials.gov/ct2/show/NCT01663402? term5odyssey&rank56. Accessed July 12, 2014.
65. The evaluation of PF-04950615 (RN316), in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1). Available at: http:// clinicaltrials.gov/ct2/show/NCT01975376?term5PF-04950615&rank513. Accessed July 12, 2014.
66. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59: 2344-53.
67. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900.
68. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
69. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380: 2007-17.
70. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo- controlled, phase 2 study. Lancet 2012;380:1995-2006.
71. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.
72. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506.
73. Blom DJ, Hala T, Bolognese M, et al, for the DESCARTES Investigators. A 52- week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19.
74. Koren MJ, Lundqvist P, Bolognese M, et al, MENDEL-2 Investigators. Anti- PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63(23):2531-40.
75. Stroes E, Colquhoun D, Sullivan D, et al, GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63(23):2541-8.
76. Robinson JG, Nedergaard BS, Rogers WJ, et al, LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311(18):1870-82.
77. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in 4 phase 2 trials. Eur Heart J 2014. http://dx.doi.org/10.1093/eurheartj/ehu085.
78. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials. J Am Coll Cardiol 2014;63:1278-88.
79. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase Subtilisin/Kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-20.
80. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2014.
81. The evaluation of PF-04950615 (RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2). Available at: http:// clinicaltrials.gov/ct2/show/NCT01975389?term5PF-04950615&rank514. Accessed July 12, 2014.
82. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-7.
83. ISIS Press Release. Bristol-Myers SQUIBB selects ISIS drug targeting PCSK9 as development candidate for prevention and treatment of cardiovascular disease. Carlsbad (CA): PRNewswire-FirstCall; 2008. Available at: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1289499. Accessed September 23, 2014.
84. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383(9911):60-8.
85. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88.
86. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two doubleblind, randomised placebo-controlled phase I studies. Lancet 2007;370: 1907-14.
87. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306(19):2099-109.
88. A study of evacetrapib in high-risk vascular disease (ACCELERATE). Available at: http://clinicaltrials.gov/show/NCT01687998. Accessed July 12, 2014.
89. REVEAL: randomized evaluation of the effects of anacetrapib through lipidmodification. Available at: http://clinicaltrials.gov/show/NCT01252953. Accessed July 15, 2014.
90. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157(2):352-60.
91. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.
92. Anacetrapib: Merck provides information about a different method to measure LDL cholesterol and progress on REVEAL study. Available at: http://www. mercknewsroom.com/press-release/research-and-developmentnews/merckprovides- update-cardiovascular-development-program. Accessed July 12, 2014.
93. FDA briefing documentNDA 203858. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM323841.pdf. Accessed July 16, 2014.